Skip to main content

Advertisement

SpringerLink
Log in

Use of the Newer Immunosuppressive Agents in Dermatology

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Summary

Immune mechanisms play a central role in various diseases such as eczema and psoriasis, and in the past treatment tended to involve corticosteroids and cytostatic drugs. Organ transplantation has stimulated the development of newer immunosuppressants, some of which have also been found to be efficacious in the inflammatory dermatoses.

The best studied such immunosuppressant is cyclosporin, which has shown efficacy especially in psoriasis and atopic dermatitis. The major limiting factor in the use of cyclosporin is its adverse effects, especially nephrotoxicity and hypertension. Therefore the risk: benefit ratio should always be considered before initiation of cyclosporin therapy, and the patient should be carefully followed for such adverse effects.

Tacrolimus seems to share the efficacy and most of the adverse effects of cyclosporin when used systemically, presumably because of its similar intracellular mechanism of action. Unlike cyclosporin, tacrolimus is efficacious topically, which may allow lower systemic adverse effects to be combined with higher local efficacy.

Other newer immunosuppressants include sirolimus (rapamycin) and monoclonal antibodies. Their use in dermatology is still in the research phase, and no conclusions about their clinical potential can yet be made.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bos JD, Kapsenberg ML. The skin immune system: its cellular constituents and their interactions. Immunol Today 1987; 7: 235–40

    Google Scholar 

  2. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136–42

    PubMed  CAS  Google Scholar 

  3. Morris R. Modes of action of FK506, cyclosporin A, and rapamycin. Transplant Proc 1994; 26: 3272–5

    PubMed  CAS  Google Scholar 

  4. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953–1040

    PubMed  CAS  Google Scholar 

  5. Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995; 1: 442–7

    PubMed  CAS  Google Scholar 

  6. Elder CA, Moore M, Chang CT et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995; 35: 865–75

    PubMed  CAS  Google Scholar 

  7. Smith SG. Neoral® (cyclosporin) in dermatology: technical aspects. Br J Dermatol 1996; 135 Suppl. 48: 2–4

    PubMed  Google Scholar 

  8. Erkko P, Granlund H, Nuutinen M et al. Comparison of cyclosporine pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. Br J Dermatol 1997 1997; 136: 82–8

    CAS  Google Scholar 

  9. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992; 326: 1654–60

    PubMed  CAS  Google Scholar 

  10. Forslund T, Hannonen P, Reitamo S et al. Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels. J Intern Med 1995; 238: 71–5

    PubMed  CAS  Google Scholar 

  11. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 1979; 301: 555

    PubMed  CAS  Google Scholar 

  12. Griffiths CEM, Powles AV, Leonard JN et al. Clearance of psoriasis with low dose cyclosporin. Br Med J Clin Res Ed 1986; 293: 731–2

    PubMed  CAS  Google Scholar 

  13. Van Joost T, Heule F, Stolz E et al. Short-term use of cyclosporin A in severe psoriasis. Br J Dermatol 1986; 114: 615–20

    PubMed  Google Scholar 

  14. Timonen P, Friend D, Abeywickrama K et al. Efficacy of lowdose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol 1990; 122: 33–9

    PubMed  Google Scholar 

  15. Christophers E, Mrowietz U, Henneicke H et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. J Am Acad Dermatol 1992; 26: 86–90

    PubMed  CAS  Google Scholar 

  16. Laburte C, Grossman R, Abi Rached et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366–75

    PubMed  CAS  Google Scholar 

  17. Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during maintenance cyclosporine therapy for psoriasis: relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995; 131: 791–5

    PubMed  CAS  Google Scholar 

  18. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis: results of a multi-dose, double-blind trial. N Engl J Med 1991; 324: 277–384

    PubMed  CAS  Google Scholar 

  19. Logan RA, Camp RDR. Severe atopic eczema: response to oral cyclosporin A. J R Soc Med 1988; 81: 417–8

    PubMed  CAS  Google Scholar 

  20. Van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol 1987; 123: 166–7

    PubMed  Google Scholar 

  21. Munro CS, Levell NJ, Shuster S et al. Maintenance treatment with cyclosporin in atopic eczema. Br J Dermatol 1994; 130: 376–80

    PubMed  CAS  Google Scholar 

  22. Granlund H, Erkko P, Sinisalo M et al. Cyclosporin A in atopic dermatitis: time to relapse and effect of intermittent therapy. BrJ Dermatol 1995; 132: 106–12

    CAS  Google Scholar 

  23. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137–40

    PubMed  CAS  Google Scholar 

  24. Wahlgren C, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol (Stockh) 1990; 70: 323–9

    CAS  Google Scholar 

  25. Van Joost T, Heule F, Korstanje M et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994; 130: 75–8

    Google Scholar 

  26. Petersen CS, Menne T. Cyclosporin Aresponsive chronic severe vesicular hand eczema. Acta Derm Venereol (Stockh) 1992; 72: 436–7

    CAS  Google Scholar 

  27. Reitamo S, Granlund H. Cyclosporin A in the treatment of chronic dermatitis of the hands. Br J Dermatol 1994; 130: 75–8

    PubMed  CAS  Google Scholar 

  28. Granlund H, Erkko P, Eriksson E et al. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol (Stockh) 1996; 76: 371–6

    CAS  Google Scholar 

  29. Knop J, Bonsman G. Ciclosporin in the treatment of progressive systemic sclerosis. In: Schindler R, editor. Cyclosporine in autoimmune disease. 1st International Symposium, Basel (Ch). Berlin: Springer-Verlag, 1985: 199–200

    Google Scholar 

  30. Appelboom T, Itkowich D. Cyclosporine in successful control of rapidly progressive scleroderma. Am J Med 1987; 82: 866–7

    PubMed  CAS  Google Scholar 

  31. Yocum DE, Wilder RL. Cyclosporin A in progressive systemic sclerosis. Am J Med 1987; 83: 369–70

    PubMed  CAS  Google Scholar 

  32. Zachariae H, Zachariae E. Cyclosporin A in systemic sclerosis. Br J Dermatol 1987; 116: 741–2

    PubMed  CAS  Google Scholar 

  33. Frances C, Branchet MC, Bletry O et al. Skin collagen from scleroderma patients before and after cyclosporin A treatment. Clin Exp Dermatol 1988; 13: 1–3

    PubMed  CAS  Google Scholar 

  34. Vayssairat M, Baudot N, Boitard C et al. Cyclosporine therapy for severe systemic sclerosis associated with the anti-Scl-70 antibody. J Am Acad Dermatol 1990; 22: 695–6

    PubMed  CAS  Google Scholar 

  35. Zachariae H, Hansen HE, Olsen TS. Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A. Acta Derm Venereol (Stockh) 1992; 72: 307–9

    CAS  Google Scholar 

  36. Clements PJ, Lachenbruch PA, Sterz M et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1988; 36: 75–83

    Google Scholar 

  37. Masuda K, Urayama A, Kogure M et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet 1989; 1: 1093–6

    PubMed  CAS  Google Scholar 

  38. Reitamo S, Puska P, Lassus A. Cyclosporin in the treatment of palmo-plantar pustulosis. Br J Dermatol 1989; 120: 857

    PubMed  CAS  Google Scholar 

  39. Meinardi M, De Rie MA, Bos JD. Oral cyclosporin A is effective in clearing persistent pustulosis palmaris et plantaris. Acta Derm Venereol (Stockh) 1990; 70: 77–9

    CAS  Google Scholar 

  40. Reitamo S, Erkko P, Remitz A et al. Cyclosporine in the treatment of palmoplantar pustulosis: a randomized double-blind, placebo-controlled study. Arch Dermatol 1993; 129: 1273–9

    PubMed  CAS  Google Scholar 

  41. Ganser G, Spieker C, Raidt H et al. Cyclosporin A bei Dermatomyositis. Schweiz Rundsch Med Prax 1984; 73: 741–3

    PubMed  CAS  Google Scholar 

  42. Zabel P, Leimenstoll G, Gross WL. Cyclosporin for acute dermatomyositis. Lancet 1984; 1: 343

    PubMed  CAS  Google Scholar 

  43. Ejstrup L. Severe dermatomyositis treated with cyclosporin A. Ann Rheum Dis 1986; 45: 612–3

    PubMed  CAS  Google Scholar 

  44. Heckmatt J, Saunders C, Peters AM et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989; 1: 1063–6

    PubMed  CAS  Google Scholar 

  45. Thivolet J, Barthelemy H, Rigot Muller G et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet 1985; 1: 334–5

    PubMed  CAS  Google Scholar 

  46. Lapidoth M, David M, Ben Amitai D et al. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994; 30: 752–7

    PubMed  CAS  Google Scholar 

  47. Barthelemy H, Frappaz A, Cambazard F et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol 1988; 18: 1262–6

    PubMed  CAS  Google Scholar 

  48. Shelley ED, Sheley WB. Cyclosporine therapy for pyoderma gangrenosum associated with sclerosing cholangitis and ulcerative colitis. J Am Acad Dermatol 1988; 18: 1084–8

    PubMed  CAS  Google Scholar 

  49. Penmetcha M, Navaratnam AE. Pyoderma gangrenosum: response to cyclosporin A. Int J Dermatol 1988; 27: 253

    PubMed  CAS  Google Scholar 

  50. Magid ML, Gold MH. Treatment of recalcitrant pyoderma gangrenosum with cyclosporine. J Am Acad Dermatol 1989; 20: 293–4

    PubMed  CAS  Google Scholar 

  51. Elgart G, Stover P, Larson K et al. Treatment of pyoderma gangrenosum with cyclosporine: results in seven patients. J Am Acad Dermatol 1991; 24: 83–6

    PubMed  CAS  Google Scholar 

  52. Matis WL, Ellis CN, Griffiths CEM et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128: 1060–4

    PubMed  CAS  Google Scholar 

  53. Granlund H, Reitamo S. Cyclosporin A in the treatment of chronic actinic dermatitis. Eur J Dermatol 1992; 2: 237–41

    Google Scholar 

  54. Ross JS, Norris PG, Hawk JLM et al. Long-term cyclosporin A in eczematous disorders. Br J Dermatol 1992; 123: 50–1

    Google Scholar 

  55. Norris PG, Camp RDR, Hawk JL. Actinic reticuloid: response to cyclosporine. J Am Acad Dermatol 1989; 21: 205–14

    Google Scholar 

  56. Toonstra J, Henquet CJM, Van Weelden H et al. Actinic reticuloid: a clinical, photobiologic, histopathologic, and follow-up study of 16 patients. J Am Acad Dermatol 1989; 21: 307–8

    Google Scholar 

  57. Duschet P, Schwartz T, Oppolzer G et al. Persistent light reaction: successful treatment with cyclosporin. Acta Derm Venereol (Stockh) 1988; 68: 176–8

    CAS  Google Scholar 

  58. Thestrup-Pedersen K, Zachariae C, Kaltoft K et al. Development of cutaneous pseudolymphoma following ciclosporin therapy of actinic reticuloid. Dermatologica 1988; 177: 376–81

    PubMed  CAS  Google Scholar 

  59. Gupta AK, Ellis CN, Coper KD et al. Oral cyclosporine for the treatment of alopecia areata: a clinical and immunohistochemical analysis. J Am Acad Dermatol 1990; 22: 242–50

    PubMed  CAS  Google Scholar 

  60. Teshima H, Urabe A, Irie M et al. Alopecia universalis treated with oral cyclosporine A and prednisolone: immunologic studies. Int J Dermatol 1992; 31: 513–6

    PubMed  CAS  Google Scholar 

  61. Boixeda JP, Soria C, Medina S et al. Bullous pemphigoid and psoriasis: treatment with cyclosporine. J Am Acad Dermatol 1991; 24: 152

    PubMed  CAS  Google Scholar 

  62. Connolly SM, Sander HM. Treatment of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol 1987; 16: 890

    PubMed  CAS  Google Scholar 

  63. Zachariae H. Cyclosporine A in epidermolysis bullosa acquisita. J Am Acad Dermatol 1987; 17: 1058–9

    PubMed  CAS  Google Scholar 

  64. Crow LL, Finkle JP, Gammon WR et al. Clearing of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol 1988; 19: 937–42

    PubMed  CAS  Google Scholar 

  65. Pigatto PDE, Chiappino G, Bigardi A et al. Cyclosporin for treatment of severe lichen planus. Br J Dermatol 1990; 122: 121–3

    PubMed  CAS  Google Scholar 

  66. Ho VC, Gupta AK, Ellis CN et al. Treatment of severe lichen planus with cyclosporine. J Am Acad Dermatol 1990; 22: 64–8

    PubMed  CAS  Google Scholar 

  67. Ho VC, Gupta AK, Ellis CN et al. Cyclosporine in lamellar ichtyosis. Arch Dermatol 1989; 125: 511–4

    PubMed  CAS  Google Scholar 

  68. Peter RU, Ruzicka T, Eckert F. Low-dose cyclosporine A in the treatment of disabling morphea. Arch Dermatol 1991; 127: 1420–1

    PubMed  CAS  Google Scholar 

  69. Worle B, Hein R, Krieg T et al. Cyclosporin in localized and systemic scleroderma — a clinical study. Dermatologica 1990; 181: 215–20

    PubMed  CAS  Google Scholar 

  70. Russell ML, Schachter RK. Cyclosporin treatment of scleroderma. Arthritis Rheum 1988; 31: 51

    Google Scholar 

  71. Mihatsch MJ, Wolff K. Consensus conference on cyclosporin A for psoriasis, February 1992. Br J Dermatol 1992; 126: 621–3

    PubMed  CAS  Google Scholar 

  72. Camp RDR, Reitamo S, Friedmann PS et al. Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993. Br J Dermatol 1993; 129: 217–20

    PubMed  CAS  Google Scholar 

  73. Gupta AK, Matteson EL, Ellis CN et al. Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 1989; 125: 507–10

    PubMed  CAS  Google Scholar 

  74. Heule F, Van Joost T, Beukers R. Cyclosporine in the treatment of lupus erythematosus. Arch Dermatol 1986; 122: 973–4

    PubMed  CAS  Google Scholar 

  75. Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses: a clinical and immunopathologic analysis. Arch Dermatol 1990; 126: 339–50

    PubMed  CAS  Google Scholar 

  76. Bourke JF, Berth-Jones J, Graham-Brown RA. Sweet’s syndrome responding to cyclosporin. Br J Dermatol 1992; 127: 36–8

    PubMed  CAS  Google Scholar 

  77. Lindholm A, Zachariae H, Reitamo S et al. Is cyclosporine blood concentration monitoring necessary in patients treated for severe chronic plaque form psoriasis?. Transplant Proc 1990; 22: 1293–5

    PubMed  CAS  Google Scholar 

  78. Silverman AK, Emmett M, Menter A. Can maintenance cyclosporine be used in psoriasis without decreasing renal function?. Semin Dermatol 1992; 11: 302–12

    PubMed  CAS  Google Scholar 

  79. Aldridge RD, Sewell HF, King G et al. Topical cyclosporin A in nickel hypersensitivity: results of a preliminary clinical and immunohistochemical investigation. Clin Exp Immunol 1986; 66: 582–9

    PubMed  CAS  Google Scholar 

  80. Hermann RC, Taylor RS, Ellis CN et al. Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1988; 1: 246–9

    PubMed  CAS  Google Scholar 

  81. Reitamo S, Kayhko K, Lauerma AI et al. Topical cyclosporine and contact dermatitis in guinea pig and man. Arch Dermatol 1989; 125: 568

    PubMed  CAS  Google Scholar 

  82. Mizoguchi M, Kawaguchi K, Ohsuga Y et al. Cyclosporin ointment for psoriasis and atopic dermatitis. Lancet 1992; 339: 1120

    PubMed  CAS  Google Scholar 

  83. Schultze HJ, Mahrle G, Steigedler GK. Topical cyclosporin A in psoriasis. Br J Dermatol 1990; 122: 113–23

    Google Scholar 

  84. Ho VC, Griffiths CEM, Ellis CN et al. Intralesional cyclosporine in the treatment of psoriasis: a clinical, immunologic, and pharmacokinetic study. J Am Acad Dermatol 1990; 22: 94–100

    PubMed  CAS  Google Scholar 

  85. Burns MK, Ellis CN, Eisen D et al. Intralesional cyclosporine for psoriasis: relationship of dose, tissue levels, and efficacy. Arch Dermatol 1992; 128: 786–90

    PubMed  CAS  Google Scholar 

  86. Mrowietz U, Christophers E. Clearing of pyoderma gangrenosum by intralesional cyclosporin A. Br J Dermatol 1991; 125: 499

    PubMed  CAS  Google Scholar 

  87. Eisen D, Ellis CN, Voorhees JJ. Topical cyclosporine for oral bullous disorders. J Am Acad Dermatol 1990; 23: 936–7

    PubMed  CAS  Google Scholar 

  88. Eisen D, Ellis CN, Duell EA et al. Effect of topical cyclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med 1990; 323: 290–4

    PubMed  CAS  Google Scholar 

  89. Surber C, Itin P, Büchner S. Clinical controversy on the effect of topical ciclosporin: what is the target site?. Dermatology 1992; 185: 242–5

    PubMed  CAS  Google Scholar 

  90. Peters DH, Fitton A, Plosker GL et al. Tacrolimus: a review of its pharmacology, and its therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746–94

    PubMed  CAS  Google Scholar 

  91. Michel G, Kemeny L, Homey B, et al. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 1996; 106

  92. De Paulis AD, Stelato C, Cirillo R et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99: 723–8

    PubMed  Google Scholar 

  93. De Paulis AD, Cirillo R, Ciccarelli A et al. Characterization of the anti-inflammatory effect of FK506 on human mast cells. J Immunol 1991; 147: 4278–85

    PubMed  Google Scholar 

  94. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharmacol Exp Ther 1992; 260: 680–8

    PubMed  CAS  Google Scholar 

  95. Fruman DA, Bierer BE, Benes JE et al. The complex of FK506- binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 1995; 154: 1846–51

    PubMed  CAS  Google Scholar 

  96. Duncan JI. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506 and rapamycin. J Invest Dermatol 1994; 102: 84–8

    PubMed  CAS  Google Scholar 

  97. Lemster BH, Carroll PB, Rilo HR et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus therapy. Clin Exp Immunol 1995; 99: 148–54

    PubMed  CAS  Google Scholar 

  98. Schultz BS, Michel G, Wagner S et al. Increased expression of epidermal IL-8 receptor in psoriasis: down-regulation by FK-506 in vitro. J Immunol 1993; 151: 4399–406

    Google Scholar 

  99. Peters DH, Fitton A, Plosker GL et al. Tacrolimus: a review of its pharmacology and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746–94

    PubMed  CAS  Google Scholar 

  100. Rilo HLR, Subbotin VM, Selby RR et al. Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. Transplantation 1995; 59: 1350–64

    Google Scholar 

  101. Yamamoto S, Jiang H, Kato R. Stimulation of hair growth by topical application of FK506, a potent immunosuppressive agent. J Invest Dermatol 1994; 102: 160–4

    PubMed  CAS  Google Scholar 

  102. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol 1995; 104: 523–5

    PubMed  CAS  Google Scholar 

  103. Abu-Elmagd K, Van Thiel D, Jegasothy BV et al. FK506: Anew therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 1991; 23: 3322–4

    PubMed  CAS  Google Scholar 

  104. European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996; 132: 419–23

    Google Scholar 

  105. Charley M, Ackerman C, Fung J et al. FK506 — a new immunomodulatory agent to treat Sezary’s syndrome. J Invest Dermatol 1991; 96: 571A

    Google Scholar 

  106. Abu-Elmagd K, Van Thiel DH, Jegasothy BV et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK506). Ann Intern Med 1993; 119: 595–8

    PubMed  CAS  Google Scholar 

  107. Lauerma AI, Maibach HI, Granlund H et al. Inhibition of contact allergy reactions by topical FK506. Lancet 1992; 340: 556

    PubMed  CAS  Google Scholar 

  108. Nakagawa H, Etoh T, Ishibashi Y et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883

    PubMed  CAS  Google Scholar 

  109. Aoyama H, Tabata N, Tanaka M et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1 % FK506 ointment. Br J Dermatol 1995; 133: 494–6

    PubMed  CAS  Google Scholar 

  110. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39–87

    Google Scholar 

  111. Meingassner JG, Stütz A. Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 1992; 99: 486–9

    CAS  Google Scholar 

  112. Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases?. J Invest Dermatol 1992; 98: 851–5

    PubMed  CAS  Google Scholar 

  113. Poizot-Martin I, Dhiver C, Mawas C et al. Are CD4 antibodies and peptide T new treatments for psoriasis?. Lancet 1991; 337: 1477

    PubMed  CAS  Google Scholar 

  114. Prinz J, Braun-Falco O, Meurer M et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991; 338: 320–1

    PubMed  CAS  Google Scholar 

  115. Nicolas JF, Chamchick N, Thivolet J et al. CD4 antibody treatment of severe psoriasis. Lancet 1991; 338: 321

    PubMed  CAS  Google Scholar 

  116. Robinet E, Stamm C, Morel P et al. Clinical improvement of a patient with severe psoriasis following CD4 antibody administration despite a blocking antibody-host response. Eur J Dermatol 1996; 6: 141–6

    Google Scholar 

  117. Rappersberger K, Meingassner JG, Fialla R et al. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996; 106: 701–10

    PubMed  CAS  Google Scholar 

  118. Noonan FP, De Fabo EC. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunol Today 1992; 13: 250–4

    PubMed  CAS  Google Scholar 

  119. Guymer RH, Mandel TE. Urocanic acid in allotransplantation. Transplant Proc 1990; 22: 2119–26

    PubMed  CAS  Google Scholar 

  120. Grüner S, Diezel W, Stoppe H et al. Inhibition of skin allograft rejection and acute graft-versus-host disease by cis-urocanic acid. J Invest Dermatol 1992; 98: 459–62

    PubMed  Google Scholar 

  121. Kurimoto I, Streilein JW. Cis-urocanic acid suppression of contact hypersensitivity induction is mediated via tumor necrosis factor-alpha. J Immunol 1992; 148: 3072–8

    PubMed  CAS  Google Scholar 

  122. Lauerma AI, Aioi A, Maibach HI. Topical cis-urocanic acid suppresses both induction and elicitation of contact hypersensitivity in BALB/C mice. Acta Derm Venereol (Stockh) 1995; 75: 272–5

    CAS  Google Scholar 

  123. Van Strien GA, Korstanje MJ. Treatment of contact hypersensitivity with urocanic acid. Arch Dermatol Res 1995; 287: 564–6

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Helsinki University Central Hospital, Meilahdentie 2, FIN-00250, Helsinki, Finland

    Antti I. Lauerma, Håkan Granlund & Sakari Reitamo

Authors
  1. Antti I. Lauerma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Håkan Granlund
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sakari Reitamo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antti I. Lauerma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lauerma, A.I., Granlund, H. & Reitamo, S. Use of the Newer Immunosuppressive Agents in Dermatology. BioDrugs 8, 96–106 (1997). https://doi.org/10.2165/00063030-199708020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199708020-00003

Keywords

Search

Navigation